Optimizing cholesterol treatment for heart health
Part of Genetic & congenital, Hormones & metabolism clinical trials.
This trial helps people with high cholesterol or a history of heart disease find the best treatment to lower their risk of future heart problems. It tests a program to optimize lipid-lowering therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have high LDL ('bad') cholesterol of 160 mg/dL or higher.
- You have very high LDL (190+) without treatment and a family history of early heart disease.
- You have had a heart attack and are not on optimal cholesterol-lowering medication.
- You have a close family member (parent, sibling, child) with early heart disease.
- You have a personal history of coronary artery disease (blockages in heart arteries).
- You have very high triglycerides (500+) or high lipoprotein(a) or high coronary calcium score.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new gene therapy called YOLT-101 for people with familial hypercholesterolemia, a genetic condition that causes very high cholesterol. The treatment aims to lower cholesterol levels and reduce heart risks.
This trial focuses on people with familial hypercholesterolemia (FH), an inherited condition that causes very high cholesterol. It aims to better understand and manage severe cholesterol problems that raise heart risk, especially in families.
This trial focuses on people referred to a cholesterol (lipid) clinic to help identify inherited high cholesterol. It tests an “interpretive comment” approach to nudge detection—meaning it may help clinicians recognize who is most likely to have familial hypercholesterolemia.
This trial aims to identify kids and teens who may have inherited high cholesterol (especially LDL) and may be at higher risk for early heart artery disease. It may help families learn about their risk and ensure the right follow-up and treatment plan.
This Phase 1 study tests a new treatment using tiny delivery particles (“exosomes”) to carry instructions (LDLR mRNA) that may help lower LDL (“bad”) cholesterol in people with homozygous familial hypercholesterolemia. The main goal is to see if it’s safe and learn how the treatment behaves in the body.
This study tests a team-based approach to help people with artery disease (like heart attacks or leg blockages) get their cholesterol to a healthier level. If your LDL is above 70, you may benefit from extra support to manage your medications.
Hear when a new Familial Hypercholesterolemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.